BACK TALK

Zika Crisis Stresses Need for Pharma Industry

When pharmaceutical companies are needed, we're Jonas Salks; when we ask to be paid, we're Martin Shkrelis.

Right-to-Try Laws Take Sensible Approach to Reforming FDA Rules

The regulator's reliance on double-blind, placebo-controlled trials with exhaustive inclusion and exclusion criteria is incompatible with today's precision medicine.

Your PharmaScope 2016

If we don't clean up our act and do something about predatory pricing scandals, we'll wind up with Washington bureaucrats telling us what we can charge for our products.

A Company's Culture Begins on Day One

If we were going to be one of a kind, we needed a staff that understood and had lived through what our clients were facing.

A Faster FDA Approval Rate Key to Price Debate

Apparently, Dr. Ezekiel Emanuel loves to open his window and shout "fire!"

Back Talk: Who's Aiming for the Feet?

That 700% price hike created an issue that threatens years of pharma progress

Back Talk: Hail to the . . . CEO?

Back Talk: Is Cost Myopia Unfocused?

Before you fire up your outrage and vent your spleen, take a long look inside your parents' (or your own) medicine chest

OPINION

Email Newsletters